Compare SMX Security Matters plc (SMX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs BIO-TECHNE Corp — how do they compare? SMX Security Matters plc trades at $3.75 (market cap $4.13M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 2750.6× SMX Security Matters plc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 21 Days and BIO-TECHNE Corp for 63 Days on average.
| SMX | TECH | |
|---|---|---|
Market Cap | $4.13M | $11.36B |
Volume | 124,362 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $74.08K | $72.61 |
52-Week Low | $3.79 | $43.31 |
Typical Hold Time | 21 Days | 63 Days |
Enterprise Value | -$27.20M | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $3.90, up 2.9% today, but faces significant financial challenges with no revenue reported for 2025 and a net loss of $169.18 million. The stock shows bearish technical signals with moving averages indicating selling pressure, though oscillators suggest potential short-term momentum. Recent news highlights the company's focus on recycled plastic verification technology and growing media coverage from major outlets.
The outlook remains highly speculative given the absence of revenue and substantial losses. Investment opportunity hinges on successful commercialization of SMX's material verification platform, while risks include cash burn sustainability and intense competition in the circular economy space. Wall Street sentiment appears cautious due to the company's unproven business model.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
